IGC Pharma
IGC
#10740
Rank
HK$0.16 B
Marketcap
HK$1.60
Share price
2.20%
Change (1 day)
-45.75%
Change (1 year)
IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) is a clinical-stage pharmaceutical company focused on developing advanced treatments for diseases, with a primary focus on Alzheimer's disease and other neurological conditions.

Earnings for IGC Pharma (IGC)

Earnings in 2026 (TTM): -HK$51.2 Million

According to IGC Pharma's latest financial reports the company's current earnings are HK$1.18 Million. In 2025 the company made an earning of -HK$41.91 Million, an increase over its 2024 earnings that were of -HK$69.1 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for IGC Pharma from 2006 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -HK$51.2 Million22.17%
2025 -HK$41.91 Million-39.35%
2024 -HK$69.1 Million-37.72%
2023 -HK$0.12 Billion1.19%
2022 -HK$0.11 Billion21.96%
2021 -HK$89.91 Million27.13%
2020 -HK$70.72 Million57.16%
2019 -HK$45 Million85.47%
2018 -HK$24.27 Million52.76%
2017 -HK$15.89 Million-16.23%
2016 -HK$18.96 Million-28.75%
2015 -HK$26.61 Million-19.59%
2014 -HK$33.1 Million6.79%
2013 -HK$31 Million-9.47%
2012 -HK$34.24 Million-74.03%
2011 -HK$0.14 Billion119.78%
2010 -HK$59.98 Million62.02%
2009 -HK$37.02 Million74.39%
2008 -HK$21.23 Million-313.12%
2007 HK$9.95 M-35.94%
2006 HK$15.54 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sterling Infrastructure
STRL
HK$6.12 B-12,021.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Trinity Industries
TRN
HK$5.72 B-11,253.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Granite Construction
GVA
-HK$0.53 Billion 915.47%๐Ÿ‡บ๐Ÿ‡ธ USA